Olivier worked for 4 global pharmaceutical companies in the US, UK, Canada, Germany and France. He is currently a senior advisor at Blackstone, a global investment firm, and a director of Alnylam Pharmaceuticals, a leading RNAi therapeutics company.
Olivier retired from Sanofi S.A., the global pharmaceutical company headquartered in Paris, in September 2019 after being its Chief Executive Officer since April 2015. Prior to joining Sanofi, Olivier was the CEO of Bayer HealthCare AG.
From 2000 to 2013, he held a series of leadership positions at Pfizer of which President and General Manager of Global specialty Care (2008-2009), Global Primary Care (2009-2012) before becoming President and General Manager of the Emerging Markets and Established Products business units. Olivier was part of the Pfizer Executive team from 2010 to 2013.
Olivier studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds a Master’s Degree in Biology and an Advanced Degree in Cellular and Immunological Pathophysiology.
During his responsibilities at Sanofi, Olivier was most recently Chairman of the Board of Management of the Pharmaceutical Research and Manufacturers of America (2019), Vice-President of the European Federation of Pharmaceutical Industries and Associations (2017-2019) and is an Honorary Fellow of the Royal College of Physicians in London.
Blackstone Life Sciences Alnylam Pharmaceuticals